Skip to main content

Table 1 Sociodemographic and clinical characteristics of 161 participants stratified by current HIV-1 RNA

From: Durability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up

  Total(N = 161) HIV-1 RNA<400 copies/mL(N = 118) HIV-1 RNA >400 copies/mL(N = 43)
Gender, N (%)    
Male 77 (48%) 60 (51%) 17 (40%)
Female 84 (52%) 58 (49%) 26 (60%)
Age (IQR) years 12.2 (9.3 - 15.3) 11.6 (8.8 - 14.6) 13.8 (12.3 - 16.2)
Age (categorical) years    
Child (≤12 years old) 72 (45%) 63 (53%) 9 (21%)
Adolescent (>12 years old) 89 (55%) 55 (47%) 34 (79%)
Time on Treatment (IQR) years 6.4 (5.3 - 7.5) 6.3 (5.2 - 7.4) 6.6 (5.5 - 7.6)
1st Line Regimen AZT or (d4T) +3TC + EFV 35 (21%) 28 (24%) 6 (14%)
AZT or (d4T) + 3TC + NVP 60 (37%) 47 (40%) 13 (30%)
2nd Line Regimen ABC +3TC + LPV/r 66 (42%) 43 (36%) 24 (56%)
Adherence as reported by physician, N (%)    
Good 121 (75%) 99 (84%) 22 (51%)
Poor 40 (25%) 19 (16%) 21 (49%)
WHO Stage    
I 2 (1%) 2 (2%) 0
II 22 (14%) 19 (16%) 3 (7%)
III 92 (57%) 64 (54%) 28 (65%)
IV 45 (28%) 33 (28%) 12 (28%)
+Original HIV-1 RNA, logcopies/mL (IQR) 1.8 (0 - 5.9) 1.6 (0 -5.3) 2.2 (0 - 5.4)
CD4 mean absolute number (IQR) 829 (538 - 1099) 929 (660 - 1160) 530 (224 -784)
++CD4 absolute number by category    
CD4 < 200, N (%) 9 (5%) 3 (3%) 6 (14%)
CD4 201-349, N (%) 13 (8%) 4 (3%) 9 (21%)
CD4 350 - 499, N (%) 13 (8%) 7 (6%) 6 (14%)
CD4 ≥ 500, N (%) 112 (70%) 96 (81%) 16 (37%)
CD4 missing, N (%) 14 (9%) 8 (7%) 6 (14%)
  1. + HIV-1 RNA from 2008-09 log transformed; ++ CD4 categories as defined by WHO.